Global Graft Versus Host Disease (GVHD) Treatment Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

Graft versus Host disease occurs after a stem cell or bone marrow transplant. High dose treatment destroy cancer cells along with that it simultaneously destroys healthy cells. Stem cell and bone marrow transplant treatments are used in reconstructing damaged cells, surrounding cancer tumors. Normally after high dose treatment, patient receives bone marrow from a donor through drip which resumes production of blood cells. Graft versus Host Disease occurs when certain types of white blood cells. This is caused due to the transplanted cells (graft) see recipient’s body (host) as exotic, thus transplanted cells attack the host body.

Scope of the Report:
This report studies the Graft Versus Host Disease (GVHD) Treatment market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Graft Versus Host Disease (GVHD) Treatment market by product type and applications/end industries.
The growing number of organ transplantation cases as one of the major factors that will have a positive impact on the growth of the market. The rise in chronic diseases across the globe has led to the growth in the need for organ transplantation. It has been observed that in 2015, the US witnessed more than 30,000 organ transplants cases, which has increased about 5% when compared to the previous year. Similarly, countries such as Australia also witnesses increasing cases of organ transplantation. This rising number of organ transplants will subsequently augment the growth prospects of the GVHD treatment market.
The Americas is expected to be the major revenue contributor to the GVHD treatment market by 2021. The increasing number of transplantation procedures and the growing healthcare infrastructure, will fuel the growth prospects of the market in this region. Moreover, the increasing cases of organ failures due to the unhealthy lifestyle and dietary habits of the people and the approvals of new drugs for the treatment of GVHD, will also drive the market’s growth in this region.
The global Graft Versus Host Disease (GVHD) Treatment market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Graft Versus Host Disease (GVHD) Treatment.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

Market Segment by Companies, this report covers
Bristol-Myers Squibb
Abbott
AbbVie
Allergan
Anterogen
Astellas Pharma
Athersys
Caladrius
Eli Lilly
GlaxoSmithKline
Glenmark
Kadmon Holdings
Osiris Therapeutics
Sanofi
Shire

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Monoclonal Antibodies
MTOR Inhibitors
Tyrosine Kinase Inhibitors
Thalidomide
Etanercept

Market Segment by Applications, can be divided into
Acute Graft Versus Host Disease (aGvHD)
Chronic Graft Versus Host Disease (cGvHD)